Pain Management Market: By  Seviority (Chronic Pain, Acute Pain By Type ( Pain Managements Drug (NSAIDS, Anesthetics, Antidepressants, Opioids, Anesthetics, Antihistamine Agents, Others), Pain Management Devices (Neurostimulation devices, Ablation Devices, Analgesic Infusion Pumps, Others), By Condition ( Cancer Pain, Musculoskeletal Pain, Neuropathic Pain, Migraine & Facial Pain, Others), By Distribution Channel ( Hospitals, Clinics, Others), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Pain Management Market size was valued at USD 38.8 billion in 2021 and is expected to reach USD 64.9 billion by 2028, at a CAGR of 7.6% during the forecast period 2022-2028. Pain management caused by the intense damage of the tissue or any other illness. Pain may be the result of injury or different diseases such as diabetic neuropathy, arthritis, osteoarthritis, sclerosis, cancer, fibromyalgia or others. The management of the pain based on the severity and type of the pain. Pain can be classified into two types based on intensity, acute and chronic. Acute pain is sudden onset of the pain whre as chronic pain is persistent, usually due to ageing. There were many pain management solutions available in the market in form of drugs, devices and therapies. The global healthcare system has been influenced by the COVID-19 epidemic. The health officials are working to stop the spread of the coronavirus by enforcing lockdown rules, and most elective and non-urgent surgeries have been postponed around the world. As per the research article published in the Indian Journal of Anaesthesia 2020, COVID-19 has a negative impact on pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also released recommendations on anaesthesia and intensive care techniques.

Global Pain Management Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Pain Management Market

Huge number of factors such as advancements in the pain management techniques such as Neurostimulation devices, increase in ageing population, and established reimbursement scenario are projected to boost the market growth over the forecast period. In addition, high rates of trauma conditions, incidence of the chronic diseases such as arthritis, and cancer expected to bolster the market growth over the forecast period. However, low awareness among the patient pool regarding the availability of low invasive pain management techniques and alternative treatment methods are expected to hamper the market growth over the forecast period.

Key Features of the Reports

  • In August 2017, Ajanta Pharma has launched eletriptan hydro bromide tablets for treatment of headaches in US market.

Global Pain Management Market Segmentation

By Type
  • Pain Managements Drug
    • NSAIDS
    • Anesthetics
    • Antidepressants
    • Opioids
    • Anesthetics
    • Antihistamine Agents
    • Others
  • Pain Management Devices
    • Neurostimulation devices
    • Ablation Devices
    • Analgesic Infusion Pumps
  • Others
  • Cancer Pain
  • Musculoskeletal Pain
  • Neuropathic Pain
  • Migraine & Facial Pain
  • Others
Distribution Channel
  • Hospitals
  • Clinics
  • Others
  • Chronic Pain
  • Acute Pain

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Competition Assessment:
  • Medtronic Plc (Ireland)
  • DJO Global Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Johnson and Johnson (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)